These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

755 related articles for article (PubMed ID: 22569112)

  • 21. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
    Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV
    Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
    Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX
    J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is drug-placebo difference in short-term antidepressant drug trials on unipolar major depression much greater than previously believed?
    Rihmer Z; Gonda X
    J Affect Disord; 2008 Jun; 108(3):195-8. PubMed ID: 18280581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis.
    Pedrelli P; Iovieno N; Vitali M; Tedeschini E; Bentley KH; Papakostas GI
    J Clin Psychopharmacol; 2011 Oct; 31(5):582-6. PubMed ID: 21869696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of placebo rates in major depressive disorder trials.
    Stolk P; Ten Berg MJ; Hemels ME; Einarson TR
    Ann Pharmacother; 2003 Dec; 37(12):1891-9. PubMed ID: 14632596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
    Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
    Trivedi MH; Corey-Lisle PK; Guo Z; Lennox RD; Pikalov A; Kim E
    Int Clin Psychopharmacol; 2009 May; 24(3):133-8. PubMed ID: 19318972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
    Nelson JC
    Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
    Carpenter DJ; Fong R; Kraus JE; Davies JT; Moore C; Thase ME
    J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-frequency repetitive transcranial magnetic stimulation accelerates and enhances the clinical response to antidepressants in major depression: a meta-analysis of randomized, double-blind, and sham-controlled trials.
    Berlim MT; Van den Eynde F; Daskalakis ZJ
    J Clin Psychiatry; 2013 Feb; 74(2):e122-9. PubMed ID: 23473357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
    Stewart DE; Wohlreich MM; Mallinckrodt CH; Watkin JG; Kornstein SG
    J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for the use of l-methylfolate combined with antidepressants in MDD.
    Fava M; Shelton RC; Zajecka JM
    J Clin Psychiatry; 2011 Aug; 72(8):e25. PubMed ID: 21899813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel approaches to drug-placebo difference calculation: evidence from short-term antidepressant drug-trials.
    Rihmer Z; Gonda X; Döme P; Erdős P; Ormos M; Pani L
    Hum Psychopharmacol; 2011; 26(4-5):307-12. PubMed ID: 21755539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
    Wisniewski SR; Chen CC; Kim E; Kan HJ; Guo Z; Carlson BX; Tran QV; Pikalov A
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):965-72. PubMed ID: 19662630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Earley WR; Guo H; Németh G; Harsányi J; Thase ME
    Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
    Hobart M; Skuban A; Zhang P; Josiassen MK; Hefting N; Augustine C; Brewer C; Sanchez R; McQuade RD
    Curr Med Res Opin; 2018 Apr; 34(4):633-642. PubMed ID: 29343128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the frequency of follow-up assessments affect clinical trial outcome? A meta-analysis and meta-regression of placebo-controlled randomized trials.
    Iovieno N; Tedeschini E; Levkovitz Y; Ameral VE; Papakostas GI
    Int J Neuropsychopharmacol; 2012 Apr; 15(3):289-96. PubMed ID: 21557881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review.
    Salloum NC; Fava M; Ball S; Papakostas GI
    Mol Psychiatry; 2020 Sep; 25(9):1967-1974. PubMed ID: 31988433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.
    Casey DE; Laubmeier KK; Eudicone JM; Marcus R; Berman RM; Rahman Z; Sheehan J
    Int J Clin Pract; 2014 Nov; 68(11):1301-8. PubMed ID: 25196314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.